Zenas BioPharma, Inc.
ZBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $10 | $5 |
| % Growth | – | -100% | 100% | – |
| Cost of Goods Sold | $5 | $43 | $0 | $0 |
| Gross Profit | -$5 | -$43 | $10 | $5 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $34 | $43 | $35 | $49 |
| G&A Expenses | $13 | $11 | $12 | $11 |
| SG&A Expenses | $13 | $12 | $12 | $11 |
| Sales & Mktg Exp. | $0 | $1 | $0 | $0 |
| Other Operating Expenses | $0 | -$43 | $0 | $0 |
| Operating Expenses | $48 | $12 | $47 | $61 |
| Operating Income | -$53 | -$55 | -$37 | -$56 |
| % Margin | – | – | -373.3% | -1,112.5% |
| Other Income/Exp. Net | $1 | $3 | $4 | $3 |
| Pre-Tax Income | -$51 | -$52 | -$34 | -$52 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$51 | -$52 | -$34 | -$53 |
| % Margin | – | – | -335.7% | -1,052.1% |
| EPS | -1.22 | -1.25 | -0.8 | -1.26 |
| % Growth | 2.4% | -56.2% | 36.5% | – |
| EPS Diluted | -1.22 | -1.25 | -0.8 | -1.26 |
| Weighted Avg Shares Out | 42 | 42 | 42 | 42 |
| Weighted Avg Shares Out Dil | 42 | 42 | 42 | 42 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$51 | -$55 | -$34 | -$56 |
| % Margin | – | – | -337.6% | -1,111.8% |